CLAIMS

1. An N-hydroxyformamidine derivative of the following formula or a pharmaceutically acceptable salt thereof:



(wherein

R^1 represents a hydrogen atom, a C_{1-4} alkyl group, a C_{1-4} alkoxy group or a halogen atom,

A represents a C_{1-10} alkylene group or a group of the following formula:



(wherein m, n and p each represent an integer of 0 to 4), and

R represents an N,N-di-C_{1-6} alkylamino group, a dioxanyl group, a C_{1-4} alkyl-substituted dioxanyl group, a C_{1-4} alkoxy-C_{1-4} alkoxy group or a group of the following formula:



(wherein s and t each represent an integer of 1 to 4, B represents a methylene group, an oxygen atom, a sulfur atom,

a nitrogen atom, a C_{1-4} alkyl-substituted nitrogen atom, a phenyl-substituted nitrogen atom or a benzyl-substituted nitrogen atom, R^2 represents a hydrogen atom or a C_{1-4} alkyl group, and r represents an integer of 0 to 2)).

2. An N-hydroxyformamidine derivative of the following formula or a pharmaceutically acceptable salt thereof:



(wherein A' represents a C_{1-10} alkylene group and R' represents an N,N-di-C_{1-6} alkylamino group, a pyrrolidinyl group, a dioxanyl group, a C_{1-4} alkyl-substituted dioxanyl group or a C_{1-4} alkoxy-C_{1-4} alkoxy group).

3. A pharmaceutical preparation, which comprises the N-hydroxyformamidine derivative according to claim 1 or 2 or a pharmaceutically acceptable salt thereof as an active ingredient.

4. The pharmaceutical preparation according to claim 3, which is an inhibitor of a 20-HETE-producing enzyme.

5. The pharmaceutical preparation according to claim 3, which is a therapeutic agent for kidney diseases, cerebrovascular diseases or cardiovascular diseases.